FDA Class II Recall: Harbin Jixianglong Biotech's Semaglutide API Faces Critical CGMP Violations
Harbin Jixianglong Biotech Co., Ltd. has initiated a Class II recall (D-0379-2026) for its Semaglutide API distributed nationwide in the U.S. This critical action stems from significant CGMP deviations, specifically the failure to complete process and bacterial endotoxin method validation before distribution. U.S. compounding pharmacies must immediately assess inventory and evaluate alternative sourcing strategies.
Critical CGMP Deviations Trigger Harbin Jixianglong Semaglutide Recall
The U.S. Food and Drug Administration (FDA) has classified a significant regulatory action as a Class II recall (D-0379-2026) involving Semaglutide Active Pharmaceutical Ingredient (API) manufactured by Harbin Jixianglong Biotech Co., Ltd., located in Haerbin, China. Initiated on February 13, 2026, this firm-initiated recall is a direct consequence of critical Current Good Manufacturing Practice (CGMP) deviations at the manufacturing facility. Specifically, the company failed to complete essential process validation and bacterial endotoxin method validation prior to distributing the Semaglutide API nationwide within the United States. For procurement directors and regulatory affairs heads, this failure signifies a fundamental breakdown in quality assurance. It indicates that the manufacturing processes for this Semaglutide API were not adequately controlled or proven to consistently produce a product meeting its predetermined specifications and quality attributes. The absence of bacterial endotoxin method validation is particularly concerning for business development executives, as it directly impacts patient safety by failing to confirm the absence of harmful pyrogens in a product intended for compounding, which could lead to severe adverse reactions in patients. This lapse in validation exposes downstream formulators to significant product liability and reputational risk, demanding immediate action to secure compliant materials.
Harbin Jixianglong Biotech's Role in U.S. Compounding API Supply
Harbin Jixianglong Biotech Co., Ltd., operating from North of Baoan Road, East of Changqing Street, Limin Development Zone, Haerbin, China, has been a supplier of Semaglutide API specifically designated for Rx compounding use only. The recalled product was distributed in various package sizes, identified by NDC codes: 1g (NDC 84385-106-01), 5g (NDC 84385-106-02), 10g (NDC 84385-106-06), 25g (NDC 84385-106-03), and 50g (NDC 84385-106-04). The affected lot is CP-030-20250711, with an expiration date of July 24th, 2027. For supply chain VPs, this recall highlights the critical importance of understanding the specific end-use designation of APIs sourced from foreign manufacturers. While the facility's overall capacity and market share data are not publicly available, its nationwide distribution pattern within the United States for a critical compounding ingredient like Semaglutide underscores its prior significance in the U.S. market. This event necessitates a re-evaluation of all foreign API suppliers, particularly those providing ingredients for compounded medications, to ensure their quality systems meet stringent U.S. regulatory expectations, regardless of their declared market segment.
Supply Chain Exposure: Immediate Impact on U.S. Compounding Pharmacies
The nationwide distribution of Harbin Jixianglong Biotech's Semaglutide API for Rx compounding use means that numerous U.S. compounding pharmacies are directly impacted by this Class II recall. Procurement directors must immediately identify and quarantine any inventory of the affected product, including all listed NDC codes and the specific Lot #: CP-030-20250711. Continued use of this unvalidated API poses significant regulatory and patient safety risks, potentially leading to further FDA enforcement actions against compounding pharmacies themselves. Supply chain VPs must recognize that this recall creates an immediate supply disruption for Semaglutide, a molecule increasingly in demand for various compounded formulations. The commercial implication is a pressing need to secure alternative, compliant sources without delay to maintain continuity of patient care and avoid compounding operational halts. Business development executives should also note that this incident could prompt increased scrutiny from state boards of pharmacy and other regulatory bodies on the quality of compounded preparations, making robust API sourcing a competitive differentiator. The financial and reputational costs of non-compliance far outweigh the perceived savings from less rigorously vetted suppliers.
Strategic Sourcing: Navigating Semaglutide API Alternatives Post-Recall
For procurement teams, the immediate challenge following the Harbin Jixianglong Biotech recall is the rapid identification and qualification of alternative Semaglutide API suppliers. Our intelligence currently does not name specific alternative suppliers for this particular API. This absence underscores the critical need for robust supplier diversification strategies and proactive qualification processes. Regulatory affairs heads must ensure that any new supplier's documentation, particularly regarding process validation and bacterial endotoxin method validation, is meticulously reviewed and verified to meet FDA standards. Geographic diversity in sourcing is also paramount to mitigate future single-point-of-failure risks. Qualification timelines for new API suppliers can be extensive, often spanning several months, involving comprehensive audits, analytical testing, and regulatory documentation review. Therefore, supply chain VPs should initiate parallel qualification efforts with multiple potential suppliers to minimize lead times and secure a stable, compliant supply. The commercial imperative is to prevent stockouts and maintain market access for compounded Semaglutide preparations, which requires significant investment in supplier relationship management and quality assurance from the outset.
Broader Regulatory Landscape: Heightened Scrutiny on Pharmaceutical Quality
While specific prior regulatory actions against Harbin Jixianglong Biotech Co., Ltd. are not detailed in our current intelligence, this Class II recall for CGMP deviations aligns with a broader trend of heightened FDA scrutiny on pharmaceutical quality, particularly concerning foreign manufacturers and critical validation processes. Recent parallel events highlight this persistent regulatory focus: Essential Wellness Pharma faced a Class II recall in June 2026 for Progesterone Injection due to sterility assurance failures, and Spectra Medical Devices initiated a Class II recall for Lidocaine HCl Injection, also in June 2026, citing sterility assurance deficiencies. These incidents, alongside Guardian Drug Co. Inc.'s recall for metallic contamination in antacids, underscore the FDA's unwavering commitment to enforcing CGMP compliance across the supply chain. For regulatory affairs heads and business development executives, this pattern signals that the FDA is actively monitoring and taking action on fundamental quality control issues. Companies relying on foreign API sources must anticipate rigorous inspections and be prepared to demonstrate comprehensive validation data for all critical manufacturing steps, including bacterial endotoxin testing, to avoid similar costly and reputation-damaging recalls. Proactive investment in quality systems and supplier oversight is no longer merely good practice, but a commercial necessity.
Remediation and Future Regulatory Actions for Harbin Jixianglong Biotech
The 'Ongoing' status of this Class II recall indicates that Harbin Jixianglong Biotech Co., Ltd. is currently engaged in addressing the CGMP deviations that led to the recall. For regulatory affairs heads, it is crucial to understand that a firm-initiated recall for such fundamental validation failures often precedes or accompanies further significant FDA enforcement actions, including the issuance of a Warning Letter or placement on an Import Alert. The company is expected to conduct a thorough root cause analysis, develop a comprehensive corrective and preventive action (CAPA) plan, and implement robust process and bacterial endotoxin method validations. The FDA will likely require detailed evidence of these remediations. Failure to adequately address these issues could result in the FDA preventing future shipments of Harbin Jixianglong Biotech's products into the U.S., severely impacting their U.S. market access. Supply chain VPs should prepare for potential long-term disruptions from this supplier and prioritize diversifying their API sourcing strategy. This event serves as a stark reminder that regulatory compliance is a continuous process, and initial product distribution without complete validation carries severe commercial and operational repercussions.